fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

NICE positive for Brukinsa (zanubrutinib) to treat marginal zone lymphoma – BeiGene

Written by | 23 Sep 2024 | Oncology

NICE:(UK): Zanubrutinib is recommended, within its marketing authorisation, as an option for treating marginal zone lymphoma in adults who have had at least 1 anti?CD20-based treatment. It is only recommended if the company provides it according to the commercial arrangement.

Why the committee made this recommendation; Standard care for marginal zone lymphoma in adults who have had at least 1 anti?CD20-based treatment is rituximab with or without chemotherapy, or chemotherapy alone. Zanubrutinib has not been directly compared in a clinical trial with standard care.

An indirect comparison of zanubrutinib with standard care suggests that zanubrutinib increases how long people have before their lymphoma gets worse and how long they live. The cost-effectiveness estimates for zanubrutinib compared with standard care are within the range NICE normally considers an acceptable use of NHS resources. So, zanubrutinib is recommended.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.